$KRYS
Krystal Biotech, Inc.

2022 Q3 Form 10-Q Financial Statement

#000171127922000047 Filed on August 08, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $19.94M $17.86M $15.91M
YoY Change 108.26% 82.29% 95.19%
% of Gross Profit
Research & Development $11.52M $10.89M $9.314M
YoY Change 89.41% 65.15% 50.2%
% of Gross Profit
Depreciation & Amortization $669.0K $494.0K $462.0K
YoY Change 41.14% 4.0% 5.48%
% of Gross Profit
Operating Expenses $31.45M $28.75M $50.22M
YoY Change 100.94% 75.4% 249.91%
Operating Profit -$31.45M -$28.75M -$50.22M
YoY Change 100.94% 75.4% 249.91%
Interest Expense $0.00 $0.00 $0.00
YoY Change -100.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$29.85M -$28.11M -$49.97M
YoY Change 91.48% 71.78% 216.03%
Income Tax
% Of Pretax Income
Net Earnings -$29.85M -$28.11M -$49.97M
YoY Change 91.48% 71.78% 215.99%
Net Earnings / Revenue
Basic Earnings Per Share -$1.17 -$1.10 -$1.99
Diluted Earnings Per Share -$1.17 -$1.10 -$1.99
COMMON SHARES
Basic Shares Outstanding 25.66M shares 25.55M shares 25.11M shares
Diluted Shares Outstanding 25.62M shares 25.55M shares 25.11M shares

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $394.4M $425.6M $434.6M
YoY Change 14.96% 15.73% 7.74%
Cash & Equivalents $186.4M $218.7M $269.3M
Short-Term Investments $208.0M $206.8M $165.3M
Other Short-Term Assets $3.158M $3.205M $3.366M
YoY Change 16.15% 45.88% 40.25%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $397.6M $428.8M $438.0M
YoY Change 14.97% 15.91% 7.93%
LONG-TERM ASSETS
Property, Plant & Equipment $157.8M $151.2M $136.9M
YoY Change 100.64% 236.24% 304.12%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $12.56M $12.90M $33.34M
YoY Change -34.72% -39.74%
Other Assets $205.0K $159.0K $157.0K
YoY Change 230.65% 44.55% 44.04%
Total Long-Term Assets $178.8M $172.6M $178.9M
YoY Change 69.83% 134.36% 380.95%
TOTAL ASSETS
Total Short-Term Assets $397.6M $428.8M $438.0M
Total Long-Term Assets $178.8M $172.6M $178.9M
Total Assets $576.4M $601.3M $616.9M
YoY Change 27.77% 35.57% 39.24%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.761M $9.229M $8.209M
YoY Change 21.11% 629.57% 345.17%
Accrued Expenses $21.68M $24.88M $51.94M
YoY Change -30.01% 50.76% 631.51%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $28.03M $34.43M $60.44M
YoY Change -21.65% 90.0% 560.95%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $7.575M $7.716M $7.883M
YoY Change 7.01% 11.87% 146.34%
Total Long-Term Liabilities $7.575M $7.716M $7.883M
YoY Change 7.01% 11.87% 146.34%
TOTAL LIABILITIES
Total Short-Term Liabilities $28.03M $34.43M $60.44M
Total Long-Term Liabilities $7.575M $7.716M $7.883M
Total Liabilities $35.61M $42.14M $68.32M
YoY Change -16.92% 68.46% 452.48%
SHAREHOLDERS EQUITY
Retained Earnings -$248.7M -$218.9M -$190.7M
YoY Change 108.99% 111.7% 119.2%
Common Stock $0.00 $0.00 $0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $540.8M $559.2M $548.6M
YoY Change
Total Liabilities & Shareholders Equity $576.4M $601.3M $616.9M
YoY Change 27.77% 35.57% 39.24%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$29.85M -$28.11M -$49.97M
YoY Change 91.48% 71.78% 215.99%
Depreciation, Depletion And Amortization $669.0K $494.0K $462.0K
YoY Change 41.14% 4.0% 5.48%
Cash From Operating Activities -$19.69M -$43.06M -$15.49M
YoY Change 171.37% 324.94% 60.48%
INVESTING ACTIVITIES
Capital Expenditures -$14.06M -$16.52M $17.19M
YoY Change -33.04% 313.7% 595.15%
Acquisitions
YoY Change
Other Investing Activities -$687.0K -$21.71M -$38.72M
YoY Change -95.75% -62.78% -2337.98%
Cash From Investing Activities -$14.74M -$38.22M -$55.91M
YoY Change -60.33% -38.66% 7384.34%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $107.0K
YoY Change -99.93%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.120M 30.70M -$542.0K
YoY Change 40.58% -15843.59% -100.38%
NET CHANGE
Cash From Operating Activities -19.69M -43.06M -$15.49M
Cash From Investing Activities -14.74M -38.22M -$55.91M
Cash From Financing Activities 2.120M 30.70M -$542.0K
Net Change In Cash -32.31M -50.58M -$71.94M
YoY Change -24.71% -30.37% -153.73%
FREE CASH FLOW
Cash From Operating Activities -$19.69M -$43.06M -$15.49M
Capital Expenditures -$14.06M -$16.52M $17.19M
Free Cash Flow -$5.632M -$26.54M -$32.68M
YoY Change -141.0% 332.24% 169.51%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Registrant Name
EntityRegistrantName
Krystal Biotech, Inc.
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38210
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-1080209
dei Entity Address Address Line1
EntityAddressAddressLine1
2100 Wharton Street
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001711279
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 701
dei Entity Address City Or Town
EntityAddressCityOrTown
Pittsburgh
dei Entity Address State Or Province
EntityAddressStateOrProvince
PA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
15203
dei City Area Code
CityAreaCode
412
dei Local Phone Number
LocalPhoneNumber
586-5830
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
KRYS
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
25664287 shares
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
218720000 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
341246000 usd
CY2022Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
206845000 usd
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
96850000 usd
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3205000 usd
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4171000 usd
CY2022Q2 us-gaap Assets Current
AssetsCurrent
428770000 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
442267000 usd
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
151214000 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
112355000 usd
CY2022Q2 us-gaap Long Term Investments
LongTermInvestments
12902000 usd
CY2021Q4 us-gaap Long Term Investments
LongTermInvestments
64371000 usd
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
8279000 usd
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
7228000 usd
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
159000 usd
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
74000 usd
CY2022Q2 us-gaap Assets
Assets
601324000 usd
CY2021Q4 us-gaap Assets
Assets
626295000 usd
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
9229000 usd
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
8398000 usd
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1417000 usd
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1041000 usd
CY2022Q2 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
23781000 usd
CY2021Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
16297000 usd
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
34427000 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
25736000 usd
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
7716000 usd
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
6983000 usd
CY2022Q2 us-gaap Liabilities
Liabilities
42143000 usd
CY2021Q4 us-gaap Liabilities
Liabilities
32719000 usd
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
2061773 shares
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
2061773 shares
CY2022Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
80000000 shares
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
80000000 shares
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
25664287 shares
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
25664287 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
25207985 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
25207985 shares
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
0 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
0 usd
CY2022Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
779583000 usd
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
734523000 usd
CY2022Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1545000 usd
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-163000 usd
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-218857000 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-140784000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
559181000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
593576000 usd
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
601324000 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
626295000 usd
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10890000 usd
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6594000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
20204000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12795000 usd
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
17863000 usd
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9799000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
33771000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
17951000 usd
CY2022Q2 us-gaap Litigation Settlement Expense
LitigationSettlementExpense
0 usd
CY2021Q2 us-gaap Litigation Settlement Expense
LitigationSettlementExpense
0 usd
us-gaap Litigation Settlement Expense
LitigationSettlementExpense
25000000 usd
us-gaap Litigation Settlement Expense
LitigationSettlementExpense
0 usd
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
28753000 usd
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
16393000 usd
us-gaap Operating Expenses
OperatingExpenses
78975000 usd
us-gaap Operating Expenses
OperatingExpenses
30746000 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-28753000 usd
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-16393000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-78975000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-30746000 usd
CY2022Q2 krys Interest Income Expense And Other Nonoperating Net
InterestIncomeExpenseAndOtherNonoperatingNet
645000 usd
CY2021Q2 krys Interest Income Expense And Other Nonoperating Net
InterestIncomeExpenseAndOtherNonoperatingNet
30000 usd
krys Interest Income Expense And Other Nonoperating Net
InterestIncomeExpenseAndOtherNonoperatingNet
902000 usd
krys Interest Income Expense And Other Nonoperating Net
InterestIncomeExpenseAndOtherNonoperatingNet
64000 usd
CY2022Q2 us-gaap Interest Expense
InterestExpense
0 usd
CY2021Q2 us-gaap Interest Expense
InterestExpense
0 usd
us-gaap Interest Expense
InterestExpense
0 usd
us-gaap Interest Expense
InterestExpense
1492000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-28108000 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-16363000 usd
us-gaap Net Income Loss
NetIncomeLoss
-78073000 usd
us-gaap Net Income Loss
NetIncomeLoss
-32174000 usd
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-348000 usd
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-24000 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1382000 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-27000 usd
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-28456000 usd
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-16387000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-79455000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-32201000 usd
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.10
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.10
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.74
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.74
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.08
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.08
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.48
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.48
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25545167 shares
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25545167 shares
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
22204659 shares
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
22204659 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25331000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25331000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21731711 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21731711 shares
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
593576000 usd
CY2022Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
55000 usd
CY2022Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
649000 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6571000 usd
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1034000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-49965000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
548554000 usd
CY2022Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
30748000 usd
CY2022Q2 us-gaap Shares Paid For Tax Withholding For Share Based Compensation
SharesPaidForTaxWithholdingForShareBasedCompensation
7500 shares
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8335000 usd
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-348000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-28108000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
559181000 usd
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
292084000 usd
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
152033000 usd
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2350000 usd
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-3000 usd
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-15812000 usd
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
430652000 usd
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
14000 usd
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4261000 usd
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-24000 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-16363000 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
418540000 usd
us-gaap Net Income Loss
NetIncomeLoss
-78073000 usd
us-gaap Net Income Loss
NetIncomeLoss
-32174000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1991000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1202000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
14619000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
6508000 usd
us-gaap Other Noncash Expense
OtherNoncashExpense
0 usd
us-gaap Other Noncash Expense
OtherNoncashExpense
1492000 usd
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
-166000 usd
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
-117000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-848000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1366000 usd
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-15000 usd
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
0 usd
krys Increase Decrease In Lease Liability
IncreaseDecreaseInLeaseLiability
-286000 usd
krys Increase Decrease In Lease Liability
IncreaseDecreaseInLeaseLiability
-175000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
24000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-680000 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
2476000 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
2795000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-58552000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-19783000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-19783000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
33706000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6462000 usd
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
147255000 usd
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
59561000 usd
us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
86829000 usd
us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
2959000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-94132000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-63064000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
30807000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
152065000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
649000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
0 usd
krys Payments For Suit Liability
PaymentsForSuitLiability
0 usd
krys Payments For Suit Liability
PaymentsForSuitLiability
7960000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
30158000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
144105000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-122526000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
61258000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
341246000 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
268269000 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
218720000 usd
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
329527000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
22234000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
10143000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1394000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
4060000 usd
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-218900000 usd
CY2022Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
425600000 usd
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the condensed consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements. Estimates are used in the following areas including stock-based compensation expense, accrued expenses, the fair value of financial instruments, the incremental borrowing rate for lease liabilities, and the valuation allowance included in the deferred income tax calculation.</span></div>
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3686862 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1688965 shares
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk and Off-Balance Sheet Risk</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to credit risk consist of cash, cash equivalents and investments. The Company’s policy is to invest its cash, cash equivalents and investments in money market funds, corporate bonds, commercial paper, government agency securities and various other bank deposit accounts. The counterparties to the agreements relating to the Company’s investments consist of financial institutions of high credit standing. The Company is exposed to credit risk in the event of default by the financial institutions to the extent amounts recorded on the condensed consolidated balance sheets are in excess of insured limits. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. The Company has no financial instruments with off-balance sheet risk of loss.</span></div>
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-28108000 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-16363000 usd
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.10
us-gaap Net Income Loss
NetIncomeLoss
-78073000 usd
us-gaap Net Income Loss
NetIncomeLoss
-32174000 usd
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25545167 shares
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25545167 shares
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
22204659 shares
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
22204659 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25331000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25331000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21731711 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21731711 shares
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.10
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.74
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.74
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.08
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.08
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.48
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.48
CY2022Q2 krys Cash Cash Equivalents And Debt Securities Available For Sale Amortized Cost
CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost
440002000 usd
CY2022Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1000 usd
CY2022Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1536000 usd
CY2022Q2 krys Cash Cash Equivalents And Debt Securities Available For Sale
CashCashEquivalentsAndDebtSecuritiesAvailableForSale
438467000 usd
CY2021Q4 krys Cash Cash Equivalents And Debt Securities Available For Sale Amortized Cost
CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost
502636000 usd
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
11000 usd
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
180000 usd
CY2021Q4 krys Cash Cash Equivalents And Debt Securities Available For Sale
CashCashEquivalentsAndDebtSecuritiesAvailableForSale
502467000 usd
CY2022Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
156365000 usd
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
116569000 usd
CY2022Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5151000 usd
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4214000 usd
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
151214000 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
112355000 usd
CY2022Q2 us-gaap Depreciation
Depreciation
494000 usd
us-gaap Depreciation
Depreciation
956000 usd
CY2021Q2 us-gaap Depreciation
Depreciation
475000 usd
us-gaap Depreciation
Depreciation
914000 usd
CY2022Q2 krys Accrued Construction In Progress Current
AccruedConstructionInProgressCurrent
14631000 usd
CY2021Q4 krys Accrued Construction In Progress Current
AccruedConstructionInProgressCurrent
9606000 usd
CY2022Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
3812000 usd
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2011000 usd
CY2022Q2 krys Accrued Payroll And Benefits
AccruedPayrollAndBenefits
2896000 usd
CY2021Q4 krys Accrued Payroll And Benefits
AccruedPayrollAndBenefits
2882000 usd
CY2022Q2 krys Accrued Preclinical And Clinical Expenses
AccruedPreclinicalAndClinicalExpenses
2094000 usd
CY2021Q4 krys Accrued Preclinical And Clinical Expenses
AccruedPreclinicalAndClinicalExpenses
1602000 usd
CY2022Q2 krys Accrued Financing Fees Current
AccruedFinancingFeesCurrent
29000 usd
CY2021Q4 krys Accrued Financing Fees Current
AccruedFinancingFeesCurrent
26000 usd
CY2022Q2 us-gaap Accrued Income Taxes
AccruedIncomeTaxes
22000 usd
CY2021Q4 us-gaap Accrued Income Taxes
AccruedIncomeTaxes
83000 usd
CY2022Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
297000 usd
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
87000 usd
CY2022Q2 krys Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
23781000 usd
CY2021Q4 krys Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
16297000 usd
CY2020Q1 krys Payment To Escrow For Reducing Lease Rentals
PaymentToEscrowForReducingLeaseRentals
2400000 usd
CY2020Q4 krys Purchase Price Of Potential Building Purchase
PurchasePriceOfPotentialBuildingPurchase
9400000 usd
CY2020Q4 us-gaap Construction In Progress Gross
ConstructionInProgressGross
10000000 usd
CY2020Q4 us-gaap Finance Lease Liability
FinanceLeaseLiability
10000000 usd
CY2020Q4 krys Payment To Escrow For Reducing Lease Rentals
PaymentToEscrowForReducingLeaseRentals
2400000 usd
CY2020Q4 krys Purchase Price Of Potential Building Purchase
PurchasePriceOfPotentialBuildingPurchase
9400000 usd
CY2020Q4 us-gaap Escrow Deposit
EscrowDeposit
1500000 usd
krys Lessor Operating Lease Liability Annual Lease Payments
LessorOperatingLeaseLiabilityAnnualLeasePayments
82000 usd
krys Cumulative Escalation Clause Percent
CumulativeEscalationClausePercent
0.10
krys Cumulative Escalation Clause Term
CumulativeEscalationClauseTerm
P5Y
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
743000 usd
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1510000 usd
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1539000 usd
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1277000 usd
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1277000 usd
CY2022Q2 krys Lessee Operating Lease Liability To Be Paid After Year Four
LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
12063000 usd
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
18409000 usd
CY2022Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
9276000 usd
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
9133000 usd
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
8279000 usd
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
7228000 usd
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1417000 usd
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1041000 usd
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
7716000 usd
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
6983000 usd
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
9133000 usd
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
8024000 usd
CY2022Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P12Y10M24D
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P14Y4M24D
CY2022Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.094
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.095
CY2022Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
391000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
800000 usd
CY2021Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
278000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
497000 usd
CY2022Q2 us-gaap Variable Lease Cost
VariableLeaseCost
71000 usd
us-gaap Variable Lease Cost
VariableLeaseCost
120000 usd
CY2021Q2 us-gaap Variable Lease Cost
VariableLeaseCost
81000 usd
us-gaap Variable Lease Cost
VariableLeaseCost
118000 usd
CY2021Q3 krys Loss Contingency Guaranteed Maximum Price To Be Paid
LossContingencyGuaranteedMaximumPriceToBePaid
83000000 usd
CY2022Q2 us-gaap Proceeds From Insurance Settlement Operating Activities
ProceedsFromInsuranceSettlementOperatingActivities
768000 usd
us-gaap Proceeds From Insurance Settlement Operating Activities
ProceedsFromInsuranceSettlementOperatingActivities
768000 usd
us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
369000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
55.24
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
876 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
74.92
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3620262 shares
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
59.75
CY2021Q4 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
227000 usd
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
198000 usd
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2043179 shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
57.00
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
31331000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1769000 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
62.19
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
39399 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
44.13
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
151642 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y1M6D
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
28341000 usd
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
536979 shares
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
47.48
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y6M
CY2022Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
11184000 usd
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
704000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
739000 usd
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
64000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
872000 usd
CY2022Q2 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
146000 usd
us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
287000 usd
CY2021Q2 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
66000 usd
us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
103000 usd

Files In Submission

Name View Source Status
0001711279-22-000047-index-headers.html Edgar Link pending
0001711279-22-000047-index.html Edgar Link pending
0001711279-22-000047.txt Edgar Link pending
0001711279-22-000047-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
krys-20220630.htm Edgar Link pending
krys-20220630.xsd Edgar Link pending
krys-20220630ex311.htm Edgar Link pending
krys-20220630ex312.htm Edgar Link pending
krys-20220630ex321.htm Edgar Link pending
krys-20220630_g1.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
krys-20220630_cal.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
krys-20220630_lab.xml Edgar Link unprocessable
krys-20220630_pre.xml Edgar Link unprocessable
krys-20220630_htm.xml Edgar Link completed
krys-20220630_def.xml Edgar Link unprocessable